Engineered Cocrystals offer an alternative solid drug form with tailored 17 physicochemical properties. Interestingly, although cocrystals provide many 18 new possibilities they also present new challenges, particularly in regard to their 19 design and large-scale manufacture. Current literature has primarily focused on 20 the preparation and characterization of novel cocrystals typically containing only 21 the drug and coformer, leaving the subsequent formulation less explored. In this 22 paper we propose, for the first time, the use of hot melt extrusion for the 23 mechanochemical synthesis of pharmaceutical cocrystals in the presence of a 24 meltable binder. In this approach, we examine excipients that are amenable to 25 hot melt extrusion, forming a suspension of cocrystal particulates embedded in a 26 pharmaceutical matrix. Using ibuprofen and isonicotinamide as a model 27 cocrystal reagent pair, formulations extruded with a small molecular matrix 28 carrier (xylitol) were examined to be intimate mixtures wherein the newly 29 formed cocrystal particulates were physically suspended in a matrix. With 30 respect to formulations extruded using polymeric carriers (Soluplus ® and 31 Eudragit ® EPO, respectively), however, there was no evidence within PXRD 32 patterns of either crystalline ibuprofen or the cocrystal. Importantly, it was 33 established in this study that an appropriate carrier for a cocrystal reagent pair 34 during HME processing should satisfy certain criteria including limited 35 interaction with parent reagents and cocrystal product, processing temperature 36 sufficiently lower than the onset of cocrystal Tm, low melt viscosity and rapid 37 solidification upon cooling. 38 3
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Introduction

39
Pharmaceutical material science is fundamental in the design and development 40 of new and improved drug delivery platforms. In particular, crystal engineering 41 has brought the possibility of designing new drug complexes (cocrystals) that 42 provide an opportunity to modify the properties of the parent drug. Possible 43 improvements include solid-state properties, aqueous solubility, dissolution rate 44 and bioavailability [1] [2] [3] , the latter being particularly important for BCS Class II 45 drugs. Undoubtedly, over the last decade, the use of crystal engineering to 46 optimise the physical properties of drugs has gained significant attention 4, 5 . This 47 may be attributed to the fact that the effective delivery of drugs to a patient in a 48 safe and cost-effective manner is significantly influenced by the physicochemical 49
properties of drug in the solid state. Moreover, cocrystals manufactured via 50 crystal engineering offer an alternative solid drug form with tailored 51 physicochemical properties and represent a significant opportunity to generate 52 intellectual property. Interestingly, although cocrystals provide many new 53 possibilities they also present new challenges, particularly in regard to their 54 design and large-scale manufacture. 55
Pharmaceutical cocrystals are multi-component molecular complexes 56
consisting of a drug and a cocrystal former (coformer) in a well-defined 57 stoichiometry, formed mainly via hydrogen bonding, halogen bonds and/or π−π 58 stacking supramolecular interactions [4] [5] [6] . The wide range of coformer properties 59 and interactions in solid and solution phase (depending upon manufacturing 60 method) provides an opportunity to alter physicochemical properties. It has 61 been previously reported that successful cocrystallization requires 62 complimentary functional groups on drug and coformer, typical examples 63 including carboxylic acids and amides 7 . 64 Cocrystals are traditionally manufactured using traditional solvent 65 evaporation 8, 9 . However, more recently there has been a strong and increasing 66 demand for clean and environmentally friendly processes that focus on green 67 methods of conducting chemical reactions in the absence of solvents. Of 68 particular relevance within the pharmaceutical arena has been the recent 69 interest in, and success of, grinding methods, for pharmaceutical 70 cocrystallisation via mechanochemical reactions [10] [11] [12] [13] . This has been driven by the 71 fact that pharmaceutical cocrystal synthesis is largely due to the formation of 72 supramolecular interactions that can be broken and reformed under mild 73 mechanical conditions. 74
Dry/neat grinding, are simple and commonly used processes for 75 mechanochemical synthesis within solid blends 14 . These techniques have 76 emerged as a useful, alternative technique to the traditional solvent-intensive 77 methods for pharmaceutical cocrystal synthesis and production. However, there 78 has been a number of reports presenting incomplete cocrystallisation using dry 79 grinding 15 . Liquid-assisted grinding has, therefore, gained considerable favour 80 because of the possibility of providing dramatically improved productivity via 81 the addition of only small amounts of liquid to a typical grinding process [16] [17] [18] [19] [20] [21] [22] [23] [24] . It 82 is, however, occasionally criticised for the unintentional production of cocrystal 83 solvates 25 . In addition, the role of the added liquid differs from case to case, 84 resulting in difficulties in clarifying reaction mechanisms 16, 20, 26 . More recently, 85 another advanced solvent-free continuous manufacturing method, hot-melt 86 extrusion (HME), has also emerged as an, easy to scale, alternative for 87 mechanochemical cocrystal synthesis [27] [28] [29] [30] [31] . Interestingly, current literature has 88 primarily focused on the preparation and characterization of novel cocrystals 89 typically containing only the drug and coformer, leaving the subsequent 90 formulation less explored 32 . IN this regard, Etter et al (1993) reported 91 cocrystallisation in the presence of a third component by solid-state grinding 33 . 92
The resulting product contained cocrystals of the complementary reagent pair, 93 as well as the additional inert component that remained unchanged following 94 cocrystal manufacture. Furthermore, cocrystals formed in the presence of the 95 inert component had the same crystal structure as cocrystals grown from 96 solution. More recently, driven by polymer-induced heteronucleation studies 34 , it 97 has also been shown that the involvement of macromolecules in the cocrystal 98 pool may also catalyse the reaction during mechanochemical preparation of 99 cocrystals 35 . The cocrystals manufactured using polymer-assisted grinding 100 methods were shown to negate the risk of generating undesirable solvates, while 101 providing excellent control over the particle size of the resultant cocrsytals. 102
Moreover, other important work has investigated cocrystal manufacture in the 103 presence of an inert excipient 36 . The effects of coformers on phase 104 transformation and release profiles of carbamazepine (CBZ) cocrystals in 105 hydroxypropyl methylcellulose (HPMC) matrix tablets were examined. It was 106 shown that HPMC partially inhibited the crystallisation of CBZ during dissolution. 107
If mechanochemical synthesis is to deliver its promise of being a clean 108 manufacturing technology, it must be shown to be capable of operating in an 109 environment devoid of solvent and be scalable. Furthermore, it is well 110 recognised that cocrystal synthesis is only one step in the development of 111 suitable oral dose formulations with other components (e.g., lubricant, glidant, 112 diluent) and unit operations (milling, sieving, blending, compression, filling) 113 being required before a successful drug product is produced. In light of the 114 above, we propose, for the first time, the use of hot melt extrusion, a solventless, 115 continuous and easily scalable technique, for the mechanochemical synthesis of 116 pharmaceutical cocrystals in the presence of a meltable binder. In this approach, 117 we examine chemically inert excipients that are amenable to hot melt extrusion, 118 forming a suspension of cocrystal particulates embedded in a pharmaceutical 119 matrix. We aim to understand if inert meltable carriers can be used to facilitate 120 the production of a solid extrudate while also acting as a catalyst for 121 cocrystallisation during melt-extrusion processing. 122
123
Selection of Formulation Components
124
Cocrystal Reagents 125
Ibuprofen (Ibu, Figure 1a ) is a BCS Class II drug 37 and has dissolution limited 126 absorption, particularly in acidic environment. Ibu has been widely used as a 127 cocrystal reagent, principally because it is inexpensive and contains a carboxylic 128 acid functional group that makes it an excellent donor to form intermolecular 129 hydrogen bonds with cocrystal reagents that possess a lone pair of electrons 38 . 130 the dissolution rate of poorly water soluble drugs 42 . In the work reported by 138 Thommes et al., (2011) HME was used to manufacture a suspension of 139 crystalline drug in a molten excipient to produce a uniform distribution of fine 140 particles. Rapid crystallization of mannitol 'fixed' the suspended drug particles 141 producing a solid homogeneous extrudate. In the work described in this article, 142
we adapt the concept of extruded crystalline suspensions and apply the 143 aforementioned preliminary criteria into matrix carrier selection. However, due 144 to thermal stability considerations, mannitol, which melts at 160°C, was not used. 145
Consequently, xylitol which melts at a significantly lower temperature was 146 employed. 147
Despite the advantages sugar alcohols offer with respect to low melt viscosity 148 and rapid solidification, extrudates may be difficult to shape post extrusion 149 owing to the rigidity of their crystalline structure. Thus, the use of thermoplastic 150 polymers was also examined. xylitol, the HME parameters were slightly modified to prevent early-stage phase 212 separation and late-stage die blockage. In particular, the processing was divided 213 into two stages: the 'feeding stage' where temperature was set at the melting 214 point of the polyol and screw speed set at 10rpm; and the 'flushing stage' where 215 temperature was set 7°C lower than the polyol melting temperature and screw 216 speed set at 50rpm ( Table 1 ). All collected products were pulverized by mortar 217 and pestle and subsequently stored in a desiccator over silica gel at room 218 temperature prior to further analyses. 
Quantification of Cocrystal Yielding 229
The peak area of the cocrystal characteristic peak at 3.3° 2Θ for each sample was 230 used to determine the cocrystal yield 43 
In-vitro Dissolution Study 285
In-vitro drug dissolution tests were conducted to evaluate solubility 286 enhancement and dissolution behaviour of the melt extruded Ibu/IsoNA 287 cocrystals in comparison with that of the unprocessed ibuprofen. Release studies 288 were performed using a Caleva dissolution tester 10ST (GB Caleva Ltd., Dorset, 289 UK) according to the BP 2011 apparatus II, paddle method. The powdered 290 samples were sieved to the same particle size [180~212μm] prior to testing. 291
Each formulation, containing equivalent to 120mg Ibu, was tested in 600mL 292 deionized water at 37±0.5°C using a paddle rotation speed of 75rpm. 3mL 293 aliquots were withdrawn from each dissolution vessel at regular time intervals 294 and filtered through a 0.45μm Millipore filter unit (MILLEX ® -GS, Millipore, 295 Carrigtwohill Co, Cork, Ireland) before being subjected to a validated HPLC 296 analysis. Immediately after sample withdrawal, 3mL of blank dissolution media 297 was added into each vessel to maintain the overall media volume. 298
299
High Performance Liquid Chromatography (HPLC) 300
The concentration of ibuprofen in each sampled aliquot was determined using 301 HPLC analysis. The HPLC system consisted of a Waters binary HPLC pump 1525, 302 a Plus Auto sampler 717, an In-line Degasser AF and a Dual λ Absorbance 303
Detector 2487 (Waters, Massachusetts, USA). Sampled aliquots were analysed at 304 220 nm using a Jupiter C18 300 column (5μm) with a length of 250 mm and a 305 diameter of 4.60 mm (Phenomenex, Macclesfield, UK). The mobile phase 306 consisted of 85% methanol and 15% deionized water containing 0.2% TFA. The 307 flow rate was set at 1 mL/min and the column chamber was maintained at 40°C 308 for the entire analytical procedure. 
333
Formation of Ibu/IsoNA Cocrystal 334
In this work we considered that Ibu and IsoNA would form a cocrystal at an 335 equimolar stoichiometric ratio [45] [46] [47] [48] . This would be facilitated by the interaction 336 of the carboxylic acid functional group of Ibu, the IsoNA amide and the N on the 337 pyridine of IsoNA 26 The addition of 10% xylitol, as shown in Figure 3 , considerably decreased the 365 value of enthalpy associated with the cocrystal peak from 148.6±0.83 J/g to 366 62.46±0.64 J/g after 2 minutes milling. In this case it is important to note that the 367 
Hot Melt Extrusion 379
Hot melt extrusion is a non-ambient process that forces materials through a 380 heated barrel. Processing parameters and formulation variables have a 381 significant impact upon the properties of extruded product. The process 382 parameters and associated observations made during HME are listed in Table 1 . yield that the conversion from the parent reagents to the cocrystal was 436
28.06±1.65%, 33.46±0.55%, 28.60±0.61% and, 28.25±0.65% for formulations 1, 437 4, 5 and, 6, respectively. Those formulations extruded with polymeric excipient, 438 on the other hand, showed no evidence of cocrystal formation. Interestingly, 439 these diffractograms (vi and vii) showed no characteristic peaks attributable to 440 Ibu either. This would suggest that Ibu had been rendered amorphous following 441 extrusion. 442
443
FTIR Spectroscopic Analysis 444
The FTIR spectra, in the 3600-2600 cm -1 and 2000-1200 cm -1 wavenumber 445 intervals, for Ibu, IsoNA, xylitol, the cocrystal reference, and the extruded 446 suspensions containing 10%, 30% and, 50% xylitol, respectively, are 447 represented in Figure 6 . The assignment of IR vibrational bands in Ibu, IsoNA 448 and the equimolar reference cocrystal obtained from solution method is listed in 449 Table 3 . The FTIR spectrum for Ibu showed a number of weak peaks in the 450 wavenumber region [3100-2900 cm -1 ] reflecting complex modes of vibrations 451 associated to C-H, C-H2 and C-H3 groups 49 ; and a very broad peak covering 452 almost the whole wavenumber range from 3400~2800 cm -1 associated to O-H 453 stretching vibrations within a carboxylic acid dimeric structure of Ibu. A sharp 454 and intense C=O stretching band at 1721.16 cm -1 was also observed for Ibu due 455 to the presence of a mono carboxylic acid group 50 . IsoNA, on the other hand, 456 showed characteristic IR bands at: (i) 3369.03 cm -1 and 3185.83 cm -1 , 457 representing asymmetric and symmetric νN-H stretching vibrations, respectively, 458 for the H-bonded primary amide groups among closely packed IsoNA 459 molecules 51, 52 ; (ii) 1668.12 cm -1 , denoting νC=O stretching of the amide carbonyl 460 group 53 ; (iii) 1622.80 cm -1 and 1594.84 cm -1 for the δN-H bending vibrations of 461 the primary amide 54 ; and (iv) 1551.45 cm -1 signifying νC=N ring stretching in the 462 heterocyclic pyridine ring structure 54, 55 . 463
As shown in Figure 1 , the the cocrystal structure involves a number of groups 464 with characteristic IR vibrational bands. They are the IsoNA amide N-H 465 (stretching and bending), the ISoNA amide C=O (stretching), and the pyridine N 466 of isoNA, as well as the carboxylic acid group of IBU. 467
The amide carbonyl and the pyridine N are two competing H-bond acceptor 468 sites in IsoNA structure. The pyridine N, however, is generally considered a 469 better acceptor 56 hydrogen bond within the heteromeric synthon 39, 57 . It was also apparent that the 490 addition of xylitol as a matrix carrier did not alter interactions between two 491 parent cocrystal reagents. The IR spectra of the cocrystal/xylitol suspensions 492 were typical of the spectrum of cocrystal with xylitol superimposed ( Figure 6 ). 493
494
Raman Spectroscopy and Mapping 495
As shown in Figure 7 , the unprocessed Ibu, IsoNA, and their equimolar cocrystal 496 showed three distinctive peaks within Raman shift region 1050.0~975.0 cm -1 . 497
Ibu exhibited a peak at 1006.13 cm -1 characteristic of aromatic ring C-C 498 stretching. IsoNA presented a very intense and well-defined peak at 993.97 cm -1 499 attributed to the pyridine ring structure. In the equimolar cocrystal, the pyridine 500 peak was broadened and the wavenumber was shifted to 1020.50 cm -1 . There 501 were two shoulders characteristic of the vibration of the aromatic ring of Ibu, as 502 well as the residual pyridine ring structure from the remaining free IsoNA. The 503 matrix carrier xylitol, on the other hand, did not show any distinctive peak 504 within this Raman shift region. It is, therefore, clear that the peak at 1020.50 cm -1 , 505 characteristic of the cocrystal, is free of interference from any other component 506 within the formulation. By plotting the intensity of this specific peak across the 507 the sampled cross-sectional area of the extrudate we can determine the 508 distribution of the cocrystal. 509 Figure 8 (a) provides a Raman map of the extrudate produced using only 510 cocrystal reagents devoid of any excipient. The peak intensity at 1020 cm -1 has 511 been used to generate the Raman map using a rainbow cubic look-up table. The 512 lookup table was generated within an ordinate range of [1000-7500 INT]. It is 513 apparent that there is a difference in the intensity of the cocrystal peak across 514 the cross-sectional area with a highly intense region focused to the outer edges 515 of the extrudate. The spectra of a number of labelled points, representing a range 516 of intensities across the map are provided for comparative purposes. 517
The mapping results shown in Figure 9 depict the intensity values of the 518 1020.50 cm -1 peak in extrudates containing different concentrations of xylitol 519 and following storage. Interestingly, the intensity of the cocrystal peak varied 520 considerably as a function of xylitol concentration and storage. When extruded 521 with 10% xylitol (Figure 9(1) ), there was an obvious and significant increase in 522 the intensity of cocrystal (relative to neat extrusion) across the cross-sectional 523 area of the extrudate. This result correlated well with results obtained from XRD 524 where the formulations containing 10% xylitol had intense diffraction bands at 525 3.3° and 17.1°. With increasing xylitol concentration in the formulation (30% 526 and 50%, respectively), the overall intensity for the characteristic cocrystal peak 527 at 1020.50 cm -1 decreased throughout the entire cross-section (Figure 9 , (2) and 528 (3)). This result was again mirrored in the XRD where the cocrystal yield 529 decreased from 33.46±0.55% to 28.25±0.65%, as the concentration of xylitol 530 increased from 10% to 50%. Importantly, after 12-month storage under 531 controlled conditions (20°C with 70% RH), an extensive increase in the intensity 532 values for the distinctive cocrystal peak at 1020 cm -1 was observed for all three 533 formulations containing xylitol (Figure 9, (4) , (5) relating to the relative quantity of cocrytal is shown in Figure 12 . Samples were 569 stored at room temperature under both desiccated and humid conditions (20°C 570 over silica gel, and 20°C with 70%RH, respectively) to evaluate changes in the 571 cocrystal content. As previously presented, formulation 4 that contained 10% 572 w/w xylitol showed a significantly higher cocrystal yield (33.46±0.55%) than the 573 neat-extruded formulation 1 (28.06±1.65%) immediately after HME processing. 574
Increasing the concentration of xylitol considerably decreased the yield for 575 formulations 5 (28.60±0.61%) and 6 (28.25±0.65%), respectively. A similar but 576 qualitative indication was also evident in the Raman maps. Interestingly, the 577 neat extruded formulation 1 showed an increase in cocrystal yield increase 578 following 12-month storage under dry (33.85±2.69%) and humid ( 
585
Pharmaceutical cocrystals offer a way to overcome the solubility issues 586 associated with BCS class II compounds while also retaining the thermodynamic 587 stability of the crystalline form of a drug 60, 61 . Conventionally, the manufacture of 588 a pharmaceutical cocrystal product is divided into two major aspects: the 589 production/synthesis of the cocrystal itself and the subsequent formulation of 590 cocrystal into a pharmaceutical dosage form. Pharmaceutical cocrystals have 591 developed significantly in the past decade with increasing number of patents 592 issued worldwide. However, at present there is still limited marketed examples 593 of pharmaceutical products involving cocrystals 62, 63 . With the recent 594 implementation of techniques such as hot-melt extrusion 28 and spray drying 64, 65 , 595 as methods of manufacturing pharmaceutical cocrystals, it has become possible 596 to combine cocrystallisation and formulation to reduce the number of 597 manufacturing steps involved in drug product manufacture. Hot-melt extrusion 598 is particularly advantageous owing to its continuous processing capability; ease 599 of scaling and it may be used to manufacture cocrystals without the need for 600 organic solvents. 601
To achieve mechanochemical synthesis of cocrystals via HME comprehensive 602 investigations must be conducted in order to develop a thorough understanding 603 of the reaction selectivity between ingredients; the most appropriate reaction 604 conditions/parameter settings for a specific system; and most importantly, the 605 selection of a suitable matrix for the cocrystal reagents. To probe this further, we 606 have processed mixtures consisting of chosen cocrystal reagents and an 'inert' 607 carrier excipient via hot melt extrusion. The principal hypothesis being that 608 Ibu/IsoNA cocrystals should be suspend in the final matrix. Consequently, the 609 HME processing temperature was set significantly lower than the Tm onset of the 610 cocrystals (approximately 120°C). The chosen carrier excipient was either a 611 pharmaceutical grade polymer (Eudragit ® EPO and Soluplus ® ) with relatively 612 low values of Tg hence lower processing temperature, or a commonly used food 613 and pharmaceutical additive, namely Xylitol, that was molten at the chosen 614 extrusion temperature. 615
For Soluplus ® and EPO there was evidence of crystalline IsoNA within the 616 matrices and negligible Ibu/IsoNA cocrystal product. Moreover, for both 617 polymeric systems, there was no evidence within XRD patterns of crystalline Ibu, 618 after extrusion. In the case of Soluplus ® , the lack of crystalline Ibu may be 619 attributed to heating the drug beyond its melting point during extrusion (92°C) 620 and entrapping the drug in a highly viscous polymer network. The entrapment of 621 Ibu molecules within rubbery and highly viscous Soluplus ® would lead to 622 reduced mobility of Ibu and consequently reduce the interaction with IsoNA, 623 limiting cocrystal yield. Conversely, when utilising EPO as a matrix carrier, 624 competition between EPO and the coformer isonicotinamide to form hydrogen 625 bonds with ibuprofen would further impact upon cocrystal yield. There have 626 been many reports of interactions between carboxylic acids and EPO [66] [67] [68] . 627
Additionally, we would expect, as with Soluplus ® , that the mixing of Ibu with 628 highly viscous rubbery EPO would physically hinder molecular interaction 629 between the cocrystal reagents limiting cocrystal yield. 630
Conversely, the small molecular weight sugar alcohol used in this study 631 (xylitol), was found to assist cocrystallization. In part, this may be attributed to 632 limited miscibility between cocrystal product and Xylitol. Indeed, polyols have 633 been shown previously to be relatively inert during extrusion 69 . Furthermore, it 634 is well accepted that low molecular weight solvents (typically volatile organic 635 solvents) can significantly improve cocrystal yield. There are many reported 636 articles describing the significant increase in yield associated with solvent-637 assisted-methods relative to neat preparation 17, 70, 71 . In comparison to Soluplus ® 638 and EPO, Xylitol is a low molecular weight (152 g/mol) carrier, with a melt 639 viscosity typically 3~4 orders of magnitude lower than the two polymeric 640 excipients. The lack of miscibility between the cocrystal and xylitol and the low 641 viscosity and hence, increased molecular mobility of cocrysal reagents appear to 642 have been key drivers in the successful production of cocrystal. Moreover, the 643 low viscosity, ease by which cocrystal may disperse throughout the melt 58 From this work, it is evident that cocrystal suspensions may be successfully 657 manufactured in a single step using extrusion provided a matrix carrier has 658 specific qualities. Potential matrix carriers should have limited ability to form 659 non-covalent interactions with all cocrystal components, a sufficiently low 660 processing temperature such that it is lower than cocrystal melting temperature 661 and rapid solidification upon cooling. 662
The improvement in the dissolution of drug compounds, when manufactured 663 as cocrystals, can be used to enhance the solubility of BCS class II drugs. It was 664 evident that the addition of small quantities of xylitol (10%) increased cocryatl 665 yield however at higher xylitol concentrations (30% and 50%), the cocrystal 666 yield was equivalent to the formulation devoid of xylitol (Formulation 1). There 667 was no evidence of crystalline ibuprofen immediately after processing, indicating 668 that residual ibuprofen was rendered amorphous. Therefore, the amorphous 669 content (as percentage of the total Ibu content) in the 30% and 50% xylitol 670 formulations were equivalent to that in the neat-extruded formulation. And the 671 amorphous Ibu content in the 10% xylitol formulation was less than that in the 672 system devoid of xylitol. 673
In drug dissolution studies, formulation 1 (devoid of xylitol) exhibited 674 significantly increased rate and extent of drug release relative to the crystalline 675 ibuprofen powder. This could be the result of a combined effect of the formation 676 of both the cocrystal and amorphous forms of ibuprofen. Although it is difficult 677 to quantify the impact of each individual form to the dissolution improvement, 678 the fact that formulations 1, 5 and 6 all had equivalent amounts of cocrystal yield 679 is suggesting that the further increased dissolution rates of formulations 5 and 6, 680 relative to formulation 1, are attributed to the presence of xylitol. 681
The enhanced dissolution rate observed for a cocrystal suspension embedded 682 in a hydrophilic matrix relative to neat cocrystal powders may be attributed to 683
(1) the cocrystal particles present in the suspension are less aggregated due to 684 the distribution within the matrix carrier, facilitated by agitation caused by 685 extrusion screw rotation and (2) improved wettability owing to the 686 hydrophilicity of the carrier 42, [72] [73] [74] [75] . For the matrix containing Soluplus ® , the 687 release of Ibu initiated rapidly due to the presence of amorphous Ibu at the 688 surface of the Soluplus ® matrix. However, the erosion of the Soluplus ® matrix 689 was significantly slower than that of formulations containing xylitol or those 690 devoid of excipient. With IsoNA rapidly dissolving into the dissolution medium 691 due to its high aqueous solubility, the rapid ingress of water into the Soluplus ® 692 matrix may have increased Ibu mobility causing clustering of the dispersed Ibu 693 molecules and their subsequent recrystallization within the matrix. Conversely, 694 the formulation containing EPO, exhibited a reduced dissolution rate. This 695 retardation of drug release may be due to the cationic nature of the polymer, the 696 interaction with the acidic drug and the inherent slow dissolution of the 697 polymeric carrier in the chosen dissolution media. 698
Many approaches have been used to enhance the dissolution performance of 699 BCS class II drugs. Cocrystals have not only been shown to improve drug release 700
properties but are also more physically stable than amorphous drug forms 701 during storage. To understand the storage stability of the extrudates cocrystal 702 suspensions were desiccated under two different conditions, namely, a dry 703 environment over silica gel, and humid condition maintained at 70%RH, both at 704 20°C for 12 months. As previously discussed, hydrogen bonds between the two 705 cocrystal reagents are stronger than that between the homo-molecules 6, 41 , it is 706 therefore of relevance to confirm if the formed cocrystal could stay unchanged 707 under pharmaceutically relevant storage conditions. Indeed, both Raman 708 mapping and PXRD patterns showed that the stored samples had varying 709 degrees of cocrystal growth as a result of aging. This is quantitatively indicative 710 of incomplete cocrystallisation during extrusion. However, both DSC and PXRD 711 analyses on extrudates immediately following manufacture showed little 712 evidence of the presence of crystalline Ibu or IsoNA. The growth of cocrystal 713 during storage may be attributed to interaction between amorphous Ibu and 714
IsoNA molecules, that subsequently form cocrystals 76 . The samples stored under 715 high humidity, in particular, showed significant cocrystal growth during storage 716 most probably due to increased global molecular mobility following ingress of 717 moisture into the xylitol matrix. Consequently, it may be concluded that even if 718 reagents are partially amorphous following extrusion and are physically 719 stabilised by the presence of a matrix carrier they may still recrystallize. This is 720 driven by the ingress of moisture, the drop in Tg, associated increase in 721 molecular mobility of the amorphous components 77 and the subsequent 722 formation of a thermodynamically favourable cocrystal product. 723 Furthermore, the incomplete cocrystal conversion may be attributed to the 724 rapid transport of material through the extrusion barrel, limiting reaction time. 725
The residence time of a typical HME process is a multifactorial-controlled 726 variable that is dependent upon factors such as the properties of the extruded 727 materials, the processing parameter settings and, the machine geometry [78] [79] [80] [81] [82] The final extrudates were examined to be intimate mixtures wherein the newly 753 formed cocrystal particulates were physically suspended in a matrix formed by a 754 'inert' carrier excipient. Importantly, it was established in this study that an 755 appropriate carrier for a cocrystal reagent pair during HME processing should 756 satisfy certain criteria including: (1) limited interaction with parent reagents and 757 cocrystal product; (2) processing temperature sufficiently lower than the onset 758 of cocrystal Tm; (3) low melting viscosity; and (4) fast solidification upon cooling. 759
In conclusion, the use of low viscosity, chemically 'inert' matrix carriers may be 760 successfully employed in the mechanochemical synthesis of pharmaceutical 761 cocrystal suspensions via HME. 762 (vii) 10wt% EPO HME; (viii) 50wt% xylitol HME; (ix) 30wt% xylitol HME; and (x) 10wt% xylitol HME. Please note: all extrudates contained ibuprofen and isonicotinamide at a 1:1 molar ratio. Conc. of Ibu (ug/mL) Time (hr) Figure 12 Yielded cocrystal content determination for freshly extruded and stored cocrystal suspension formulations containing (from left to right): 0%, 10%, 30% and, 50%, w/w xylitol. Brittle strand a Note that the weight ratios tabulated here provide 1:1 molar ratio for Ibu and IsoNA in the blends. The batch size was maintained at approximately 10g for each formulation and the extrudates were collected after equilibration for 5 minutes. 
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